ENTYVIO
ENTYVIO (vedolizumab) is a monoclonal antibody that helps the body’s immune system by targeting and destroying certain cells that may cause inflammation. Specifically, it is an integrin receptor antagonist used in adults for the treatment of moderate to severely active Ulcerative Colitis (UC) and moderately to severely active Crohn’s disease.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
What it treats
Crohn’s disease & Ulcerative Colitis (UC)
Prescribed by
Gastroenterologists
How it’s administered
Intravenous (IV) infusion
Frequency
Initial dose, then every two weeks for two doses, then six weeks later & then every eight weeks
Length of treatment
30 minutes to one hour